Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps

Gut

Volumn 61, Issue 5, 2012, Pages 739-745

  Wu, Chung Wah ^a   Ng, Simon S M ^a   Dong, Yu Juan ^a   Ng, Siew Chien ^a   Leung, Wing Wa ^a   Lee, Chung Wa ^a   Wong, Yee Ni ^a   Chan, Francis K L ^a   Yu, Jun ^a   Sung, Joseph J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 21; MICRORNA 92A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER SURGERY; CANCER TISSUE; CLINICAL FEATURE; COLON POLYP; COLORECTAL CANCER; COLORECTAL POLYP; CONTROLLED STUDY; FEASIBILITY STUDY; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECTUM POLYP; RNA ANALYSIS; RNA STABILITY; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; FECES; FEMALE; HUMANS; INTESTINAL POLYPS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84859603174     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2011.239236     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Sung JJ, Lau JY, Young GP, et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008;57:1166-76.
3. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14. (Pubitemid 39665324)
4. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149:441-50; W81.
5. Davidson LA, Lupton JR, Miskovsky E, et al. Quantification of human intestinal gene expression profiles using exfoliated colonocytes: a pilot study. Biomarkers 2003;8:51-61. (Pubitemid 36109105)
6. Hamaya Y, Yoshida K, Takai T, et al. Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer 2010;102:916-21.
7. Leung WK, To KF, Man EP, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol 2007;102:1070-6. (Pubitemid 46698227)
8. Takai T, Kanaoka S, Yoshida K, et al. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2009;18:1888-93.
9. Kanaoka S, Yoshida K, Miura N, et al. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004;127:422-7. (Pubitemid 39091890)
10. Davies RJ, Freeman A, Morris LS, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002;359:1917-19. (Pubitemid 34615772)
11. Kim Y, Lee S, Park S, et al. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci 2003;33:32-8. (Pubitemid 36336997)
12. Hardt PD, Toepler M, Ngoumou B, et al. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003;23:851-3. (Pubitemid 36750884)
13. Pucci S, Bonanno E, Sesti F, et al. Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol 2009;104:2807-15.
14. Bandres E, Cubedo E, Agirre X, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006;5:29.
15. Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A 2006;103:3687-92. (Pubitemid 43376616)
16. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8. (Pubitemid 40839735)
17. Michael MZ, O' Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-91. (Pubitemid 37288707)
18. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61. (Pubitemid 43271657)
19. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36. (Pubitemid 351185951)
20. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
21. Ahmed FE, Jeffries CD, Vos PW, et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009;6:281-95.
22. Link A, Balaguer F, Shen Y, et al. Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010;19:1766-74.
23. Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 2010;3:1435-42.
24. Chim SS, Shing TK, Hung EC, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008;54:482-90. (Pubitemid 351348154)
25. Brown LF, Fraser CG. Effect of delay in sampling on haemoglobin determined by faecal immunochemical tests. Ann Clin Biochem 2008;45:604-5.
26. van Rossum LG, van Rijn AF, van Oijen MG, et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer 2009;125:746-50.
27. Yu Z, Hecht NB. The DNA/RNA-binding protein, translin, binds microRNA122a and increases its in vivo stability. J Androl 2008;29:572-9.
28. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-18.
29. Bail S, Swerdel M, Liu H, et al. Differential regulation of microRNA stability. RNA 2010;16:1032-9.
30. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, et al. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 2009;101:707-14.